Clinical Trials on C. Difficile Infection in Poland

Total 2867 results

Vedanta Biosciences, Inc.

Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection (RESTORATiVE303)

Clostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection

United States
Finch Research and Development LLC.
Medpace, Inc.

Completed

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT)

Clostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal Transplant

United States, Canada
Astellas Pharma Europe Ltd.
Cubist Pharmaceuticals LLC

Terminated

A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System (FREEDOM)

Clostridium Difficile

Spain, France, Germany, Greece, Denmark, Austria, Poland
Finch Research and Development LLC.

Terminated

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) (PRISM4)

Recurrent C. Difficile Infection

United States, Canada
Vedanta Biosciences, Inc.

Completed

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection (CONSORTIUM)

Clostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection Recurrence

United States, Canada
Microbiome Health Research Institute
Brown University; Tufts Medical Center; Indiana University; Edward Hospital

Terminated

Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection (STOOL)

Clostridium Difficile

United States
Finch Research and Development LLC.

Completed

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff (PRISM3)

Clostridium Difficile Infection Recurrence

Canada, United States
The Miriam Hospital

Unknown

Gut Microbiota Changes After Fecal Microbiota Transplantation

Clostridium Difficile Infection

United States
Seres Therapeutics, Inc.
Syneos Health

Completed

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) (ECOSPOR)

Clostridium Difficile

United States
Astellas Pharma Europe Ltd.

Completed

Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) (PROFILE)

Inflammatory Bowel Disease (IBD) | Clostridium Difficile Infection (CDI)

Austria, France, Greece, Italy, Poland, Russian Federation, United Kingdom
Summit Therapeutics

Completed

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection (Ri-CoDIFy 1)

Clostridioides Difficile Infection

United States, Australia, Greece, Canada, Spain, Brazil, Poland, Korea, Republic of, Argentina, Bulgaria, Hungary, New Zealand, Romania, Russian Federation
Astellas Pharma Europe Ltd.
Merck Sharp & Dohme LLC

Completed

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population (EXTEND)

Clostridium Difficile

Greece, Spain, Russian Federation, Denmark, Austria, Belgium, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania, Slovenia, Sweden, Switzerland, Turkey, United Kingdom
Erasmus Medical Center

Recruiting

Self-testing for HCV Re-infection in MSM (SELFIE)

HIV-1-infection | Hepatitis C Recurrent

Netherlands
Rebiotix Inc.

Completed

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

Clostridium Difficile Infection (CDI)

United States, Canada
Public Health Service of Amsterdam
ZonMw: The Netherlands Organisation for Health Research and Development; Amsterdam... and other collaborators

Recruiting

Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men (ICECREAM)

Hepatitis C Virus Infection

Netherlands, France
Medical University of Gdansk

Recruiting

L. Plantarum 299v and Gut Microbiome, Diarrhoea, and Clostridioides Difficile Infection in Colorectal Cancer Patients

Diarrhea | Colorectal Cancer | Clostridioides Difficile Infection

Poland
Lazarski University

Completed

Duble Lumen Intubation

Intubation; Difficult or Failed | Difficult Airway | Intubation;Difficult

Poland
Pfizer

Completed

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Clostridium Difficile Associated Disease

United States
Inspira Medical AB
NasVax Ltd

Unknown

Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects

Chronic Hepatitis C

Austria, Poland
Synthetic Biologics Inc.

Completed

A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

Clostridium Infections | Clostridium Difficile

United States, Bulgaria, Canada, Hungary, Poland, Romania, Serbia
Dynavax Technologies Corporation
PPD; Synteract, Inc.

Completed

Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Chronic Hepatitis C

Poland
Pfizer

Completed

A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years

Clostridium Difficile Associated Disease

United States
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Hepatitis C Virus Infection

United States, Puerto Rico
Gilead Sciences

Terminated

Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection

Poland, Italy, United Kingdom
Medical University of Warsaw

Recruiting

Possible Differences in HCC Course Depending on DAA Treatment

Liver Cirrhosis | Carcinoma, Hepatocellular | Hepatitis C, Chronic | Drug Effect | Hepatitis C Virus Infection, Response to Therapy of | Drug Side Effect

Poland
Actelion

Terminated

Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)

Clostridium Difficile Infection

United States, Belgium, Canada, Czechia, Hungary, Italy, Poland, Romania, Spain
Valneva Austria GmbH

Completed

Virological Response Study of the HCV Vaccine IC41

Chronic Hepatitis C

Germany, Poland, Romania
Merck Sharp & Dohme LLC

Completed

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

HCV Infection

United States, Germany, Poland, Sweden
American Gastroenterological Association
University of Pennsylvania; University of California, San Diego; University of... and other collaborators

Recruiting

Fecal Microbiota Transplant National Registry (FMT)

Clostridium Difficile Infection | Gut Microbiome | Fecal Microbiota Transplantation

United States, Canada
Hoffmann-La Roche

Completed

A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C

Hepatitis C, Chronic, Healthy Volunteer

Poland, France, Netherlands
Tibotec BVBA

Terminated

TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin

Hepatitis C Virus

Poland, Netherlands
Pfizer

Completed

Clostridium Difficile Vaccine Efficacy Trial (Clover)

Clostridium Difficile Infection

United States, Spain, Belgium, Taiwan, Japan, Portugal, Colombia, Korea, Republic of, Poland, Australia, Germany, Canada, Argentina, Bulgaria, Chile, Czechia, Finland, France, Hungary, Peru, Slovakia, Sweden, United Kingdom
Pfizer

Completed

Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age

Clostridium Difficile Associated Disease

United States
Pfizer

Completed

Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study

Clostridium Difficile Associated Disease

United States
Vertex Pharmaceuticals Incorporated

Terminated

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Virus Infection

United States, New Zealand
Colleen Kelly

Unknown

Fecal Transplant for Relapsing C. Difficile Infection

Clostridium Difficile

United States
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Chronic Hepatitis C Infection

United States, Spain, United Kingdom, Canada, Germany, France, Austria, Poland, Belgium, Czech Republic, Italy
Astellas Pharma Europe B.V.
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) (SUNSHINE)

Clostridium Difficile-associated Diarrhea (CDAD)

United States, Belgium, Italy, Canada, France, Germany, Hungary, Poland, Romania, Spain
Seres Therapeutics, Inc.

Completed

ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection (ECOSPORIII)

Clostridium Difficile Infection

United States, Canada
Merck Sharp & Dohme LLC

Completed

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001) (MODIFY III)

Clostridium Difficile Infection

United States, Argentina, Brazil, Colombia, Czechia, Germany, Hungary, Malaysia, Mexico, Norway, Poland, Portugal, Romania, South Africa, Spain, Sweden, United Kingdom
Gilead Sciences

Terminated

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

HCV Infection

United States, United Kingdom, Germany, Canada, Puerto Rico, Poland
Gilead Sciences

Terminated

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Hepatitis C Virus Infection

United States, United Kingdom, Australia, Germany, Italy, New Zealand, Belgium, Poland, Russian Federation
Actelion

Completed

Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea

Clostridium Difficile Infection

United States, Australia, Brazil, Canada, France, Germany, Italy, Netherlands, Peru, Poland, Romania, Spain
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

New Zealand, Poland, France
Bristol-Myers Squibb

Terminated

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV (DIMENSION)

Chronic Hepatitis C Infection

France, Germany, United States, Spain, Canada, Argentina, Mexico, Belgium, Italy, Russian Federation, United Kingdom, Poland
Seres Therapeutics, Inc.

Completed

ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection

Clostridioides Difficile Infection

United States, Canada
Sanofi Pasteur, a Sanofi Company

Terminated

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Clostridium Difficile Infection

Sweden, United States, Mexico, Philippines, Singapore, Germany, France, Canada, Australia, Peru, Colombia, Brazil, Costa Rica, Denmark, Dominican Republic, Finland, Guatemala, Japan, Korea, Republic of, Panama, Poland, Puerto Rico, ... and more
Gilead Sciences

Completed

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

HCV Infection

United States
Foundation for Liver Research
Janssen-Cilag B.V.

Completed

Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms (ETIM)

Chronic Hepatitis C

Netherlands
VA Office of Research and Development
University of Wisconsin, Madison

Active, not recruiting

Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA (GLORI)

Clostridium Difficile

United States

Clinical Trials on C. Difficile Infection in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations